The MCO-010 vector uses surviving cells in the retina to produce a photosensitive protein that may help patients regain some ...

Treatment introduces an expansion of the scope of gene therapies that might lead to similar treatments for neurodegenerative ...

After three patients died, the maker of an investigational gene therapy stopped shipments of the drug after it refused to ...

Cirrus’ lead program is a novel AAV gene therapy designed to restore IRAK-M, a central regulator of the eye’s immune homeostasis, so as to ...

Preliminary results from a small trial offer the clearest evidence yet that the brain disease’s progression can be slowed.

Stanford researchers and their collaborators have revealed a new device that could change the way scientists conduct ...

Three draft recommendation documents published on Wednesday are intended to guide drug sponsors and accelerate the ...

Cirrus Therapeutics secured an $11 million seed financing led by ClavystBio. Polaris Partners and SEEDS also joined in the ...

How cell and gene therapy developers can lessen the chances of receiving FDA complete response letters through the use of ...

Universities must do more to provide students with cell and gene therapy manufacturing skills, according to a new study.

Results from a three-year trial suggest an experimental gene therapy for Huntington's disease can slow the progression of the ...